Roche lifts full-year outlook after H1 sales rise 18%
July 25, 2019 at 01:19 AM EDT
Swiss drugmaker Roche lifted its full-year sales outlook after revenue in the first half rose 18 percent, helped by newer drugs including multiple sclerosis medicine Ocrevus and cancer immunotherapy Tecentriq.
